Recruiting
Phase 3

RAS(ON) Inhibitor

Sponsor:

Revolution Medicines, Inc.

Code:

NCT07252232

Conditions

Pancreatic Cancer

PDAC

PDAC - Pancreatic Ductal Adenocarcinoma

Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

Resected Pancreatic Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

daraxonrasib

Study Details

Brief summary:

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Conditions

Pancreatic Cancer

PDAC

PDAC - Pancreatic Ductal Adenocarcinoma

Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

Resected Pancreatic Adenocarcinoma

Study ID

NCT07252232

Start date

Dec 15, 2025

Status verified date

Aug, 2026

Completion date

Jul 10, 2030

Anticipated

Primary completion date

May 10, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • At least 18 years old and has provided informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histologically confirmed PDAC with successful (R0/R1) curative intent surgical resection and no evidence of recurrent or metastatic disease.
  • Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy.
  • Must have completed most recent treatment within the past 12 weeks.
  • Adequate organ function (bone marrow, liver, kidney, coagulation).
  • Documented RAS mutation status.
  • Able to take oral medications.

Exclusion Criteria:

  • Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors).
  • Any conditions that may affect the ability to take or absorb study drug.
  • Major surgery within 28 days prior to randomization.
  • Patient is unable or unwilling to comply with protocol-required study visits or procedures.

Study Design

Enrollment

500 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: daraxonrasib

study drug

no intervention: SOC Observation

Patients randomized to the comparator control arm will receive SOC observation.

Interventions

daraxonrasib

oral tablets

Primary outcome measure

  • Disease-Free Survival (DFS) per Investigator [ Time Frame: Up to approximately 5 years ]

Central Contacts and Locations

Central contacts

Revolution Medicines Study Director

1-844-2-REVMEDmedinfo@revmed.com

Locations

Mayo Clinic

Recruiting

Phoenix, Arizona, United States, 85054

Contacts

Tanios Bekaii-Saab

480-342-4800bekaii-saab.tanios@mayo.edu

UC San Diego Moores Cancer Center

Recruiting

La Jolla, California, United States, 92037

Contacts

Shakeela Dad

858-822-5376sdad@health.ucsd.edu

Cedars-Sinai Cancer at Cedars-Sinai Medical Center

Recruiting

Los Angeles, California, United States, 90048

Contacts

Naomi Geier

310-423-4693naomi.geier@cshs.org

University of California, Los Angeles

Recruiting

Los Angeles, California, United States, 90404

Contacts

Madeleine Manahan

310-633-8400mmanahan@mednet.ucla.edu

Stanford Cancer Institute

Recruiting

Palo Alto, California, United States, 94304

Contacts

Cassandra Blake

650-725-9895cblake1@stanford.edu

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94143

Contacts

Kevin Lopez

415-502-3310Kevin.lopez@ucsf.edu

Rocky Mountain Cancer Centers, LLP

Recruiting

Lakewood, Colorado, United States, 80228

Contacts

Jennifer Hege

303-388-4876jennifer.hege@usoncology.com

Hartford Healthcare

Recruiting

Hartford, Connecticut, United States, 06103

Contacts

Jonathan Steinmetz

860-972-4183jonathan.steinmetz@hhchealth.org

Mayo Clinic

Recruiting

Jacksonville, Florida, United States, 32224

Contacts

Hani Babiker

520-626-7866babiker.hani@mayo.edu

University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center

Recruiting

Miami, Florida, United States, 33136

Contacts

Yolanda Justal

305-243-2647yxj512@med.miami.edu

Florida Cancer Specialists

Recruiting

St. Petersburg, Florida, United States, 33701

Contacts

Study Coordinator

727-216-1143

Winship Cancer Institute, Emory University

Recruiting

Atlanta, Georgia, United States, 30322

Contacts

Kathleen Coleman

404-251-1278kathleen.marie.coleman@emory.edu

Community Health Network

Recruiting

Indianapolis, Indiana, United States, 46250

Contacts

Adam Norris

317-621-3858anorris@ecommunity.com

University of Kansas Medical Center Research Institute, Inc.

Recruiting

Lawrence, Kansas, United States, 66045

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins & Sibley Memorial Hospital

Recruiting

Baltimore, Maryland, United States, 21287

Contacts

GI Clinical Trial Referrals

410-614-3644giclinicaltrials@jhmi.edu

Mike Pishvaian

202-660-6500

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, United States, 02114

Dana Farber Cancer Institute (DFCI)

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

617-632-3000

Mayo Clinic Cancer Center

Recruiting

Rochester, Minnesota, United States, 55905

Contacts

Ryan Carr

507-284-2511carr.ryan@mayo.edu

Saint Luke's Cancer Institute

Recruiting

Kansas City, Missouri, United States, 64111

Contacts

Marc Roth

816-932-2677mroth@saint-lukes.org

University of Nebraska Medical Center

Recruiting

Omaha, Nebraska, United States, 68198

Comprehensive Cancer Centers of Nevada

Recruiting

Las Vegas, Nevada, United States, 89169

Contacts

Ann Lovelace

702-609-9460ann.lovelace@usoncology.com

Laura and Issac Perlmutter Cancer Center at NYU Langone-Ambulatory Care Center

Recruiting

New York, New York, United States, 10016

Contacts

Mark Bond

212-731-6120Ct.gov@nyulangone.org

Jennifer Coffey

212-731-6120Ct.gov@nyulangone.org

Columbia University Medical Center

Recruiting

New York, New York, United States, 10032

Contacts

cancerclinicaltrials@cumc.columbia.edu

Memorial Sloan Kettering Cancer Center

Recruiting

New York, New York, United States, 10065

Contacts

Eileen O'Reilly

646-888-4182oreillye@MSKCC.ORG

University of Rochester Medical Center

Recruiting

Rochester, New York, United States, 14642

Contacts

Richard Dunne

585-275-4401WCICTOResearch@URMC.Rochester.edu

Duke Cancer Center

Recruiting

Durham, North Carolina, United States, 27710

Taylor Cancer Research Center

Recruiting

Maumee, Ohio, United States, 43537

Contacts

Stephanie Ambrose

567-402-4502sambrose@tcrcpt.org

Avera Cancer Institute

Recruiting

Sioux Falls, South Dakota, United States, 57105

Contacts

Heidi McKean

605-322-6900heidi.mckean@avera.org

SCRI Oncology Partners

Recruiting

Nashville, Tennessee, United States, 37203

Texas Oncology - DFW

Recruiting

Dallas, Texas, United States, 75246

Texas Oncology - Northeast Texas

Recruiting

Longview, Texas, United States, 75601

Contacts

Angie Smith

Angie.smith2@usoncology.com

University of Utah, Huntsman Cancer Institute

Recruiting

Salt Lake City, Utah, United States, 94112

Contacts

Susan Sherry

801-585-3453susan.sharry@hci.utah.edu

Virginia Cancer Specialists

Recruiting

Fairfax, Virginia, United States, 22031

Froedtert Hospital and the Medical College of Wisconsin

Recruiting

Milwaukee, Wisconsin, United States, 53226

Contacts

Dawn Carini

414-805-0789dcarini@mcw.edu

More Information

Sponsor

Revolution Medicines, Inc.

Last update posted

Aug 25, 2026

Last verified

Aug, 2026

Keywords

  • Pancreatic Cancer
  • PDAC
  • Pancreatic Ductal Adenocarcinoma
  • RAS
  • KRAS
  • NRAS
  • HRAS
  • RAS Wild-Type
  • RASolute
  • Resectable Pancreatic Ductal Adenocarcinoma
  • Resectable PDAC
  • Resected Pancreatic Adenocarcinoma
  • RAS Mutation

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Revolution Medicines, Inc. on 2026-08-25.